Secondary hyperparathyroidism: Pathophysiology and treatment

Journal of the American Board of Family Medicine

Volumn 22, Issue 5, 2009, Pages 574-581

  Saliba, Wissam ^a   El Haddad, Boutros ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM SALT; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; RENVELA; SEVELAMER; SEVELAMER CARBONATE; TUMS; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; METABOLIC ACIDOSIS; PATHOPHYSIOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC;

EID: 70349097172     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2009.05.090026     Document Type: Review

References (30)

1. Poggio ED, Rule AD. A critical evaluation of chronic kidney disease-should isolated reduced estimated glomerular filtration rate be considered a 'disease'? Nephrol Dial Transplant 2009;24:698-700.
2. Coresh J, Selvin E, Stevens L, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047 (Pubitemid 350074801)
3. Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009;44:666-670
4. Biber J, Custer M, Magagnin S, et al. Renal Na/Picotransporters. Kidney Int 1996;49:981.
5. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997;20:303-309
6. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-2540 (Pubitemid 26187341)
7. Holick MF. Vitamin D and the kidney. Kidney Int 1987;32:912-929
8. Nabeshima Y. Clinical discovery of alpha-Klotho and FGF-23 unveiled new insight into calcium and phosphate homeostasis. Calcium 2008;18:923-934
9. Kovesdy CP, Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 2008;40:427-440
10. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D. PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38
11. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530
12. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617 (Pubitemid 28158000)
13. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008;73:1345-1354 (Pubitemid 351770492)
14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3):S1-201.
15. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003;16:186-188
16. Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006;48:37-49.
17. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-396
18. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102.
19. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252
20. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72:1130-1137 (Pubitemid 47609037)
21. Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22:2856-2866 (Pubitemid 350093462)
22. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-391 (Pubitemid 350258767)
23. Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65:191-202.
24. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4: 178-185
25. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007;147:840-853 (Pubitemid 351664426)
26. Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 1997; 77:267-272
27. Cuppari L, Garcia-Lopes MG. Hypovitaminosis d in chronic kidney disease patients: prevalence and treatment. J Ren Nutr 2009;19:38-43.
28. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456 (Pubitemid 36910023)
29. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 2005;67:760-771
30. Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 1997;82:85-86 (Pubitemid 27243675)